NP-Led Outreach Ups Cancer Screening in Rural Women Veterans

Published Date: 22 May 2026

A nurse practitioner-led outreach program improves the rates of breast and cervical cancer screening among women veterans in rural areas, a retrospective study shows.

Read Full News

Latest News

First-Line Combo Therapies Best Chemo Alone in NSCLC Trials

New phase 3 data add to a growing number of EGFR-directed first-line options for advanced NSCLC with EGFR exon 20 insertions.

3D Mammography Improves Long-Term Cancer Risk Prediction

Researchers develop and validate a deep learning model using longitudinal 3D tomosynthesis examinations to predict individualized 5-year risk for breast cancer.

Osimertinib's OS Benefit in Resected NSCLC Persists 8 Years

Even years after treatment ends, adjuvant osimertinib brings an overall survival benefit to patients with resected EGFR-mutated lung cancer.

New Data Put ADCs on the Map in Relapsed SCLC

Two B7-H3-directed antibody-drug conjugates substantially improve survival over topotecan among patients with relapsed small cell lung cancer — pointing to a potential new treatment class.

Pelvic RT Tied to Longer Survival in Cervical Cancer

In patients with newly diagnosed stage IVB cervical cancer, adding definitive-dose pelvic radiotherapy to chemotherapy was associated with longer survival compared with chemotherapy alone.

Real-World Liso-Cel Results in MCL Consistent With Trials

Two analyses of liso-cel CAR T-cell therapy in relapsed or refractory mantle cell lymphoma show response rates in the real-world setting similar to those seen in clinical trial populations.

Todays Updates

Annual Cancer Report Highlights Advances, Funding Threats

A yearly report from the American Association for Cancer Research lauds recent breakthroughs but warns on threatened federal funding changes.

Does Telenursing Improve QOL in Breast Cancer?

A meta-analysis assesses the effect of nurse-led telenursing on the quality of life in women with breast cancer.

Long-Term Results Favor Acalabrutinib Combo in MCL

The 50-month follow-up of the ECHO trial underscores greater benefits with concurrent vs sequential addition of acalabrutinib to bendamustine and rituximab.

Todays Updates

Annual Cancer Report Highlights Advances, Funding Threats

A yearly report from the American Association for Cancer Research lauds recent breakthroughs but warns on threatened federal funding changes.

Does Telenursing Improve QOL in Breast Cancer?

A meta-analysis assesses the effect of nurse-led telenursing on the quality of life in women with breast cancer.

Long-Term Results Favor Acalabrutinib Combo in MCL

The 50-month follow-up of the ECHO trial underscores greater benefits with concurrent vs sequential addition of acalabrutinib to bendamustine and rituximab.

Latest News

New phase 3 data add to a growing number of EGFR-directed first-line options for advanced NSCLC with EGFR exon 20 insertions.

Researchers develop and validate a deep learning model using longitudinal 3D tomosynthesis examinations to predict individualized 5-year risk for breast cancer.

Even years after treatment ends, adjuvant osimertinib brings an overall survival benefit to patients with resected EGFR-mutated lung cancer.

Two B7-H3-directed antibody-drug conjugates substantially improve survival over topotecan among patients with relapsed small cell lung cancer — pointing to a potential new treatment class.

In patients with newly diagnosed stage IVB cervical cancer, adding definitive-dose pelvic radiotherapy to chemotherapy was associated with longer survival compared with chemotherapy alone.

Two analyses of liso-cel CAR T-cell therapy in relapsed or refractory mantle cell lymphoma show response rates in the real-world setting similar to those seen in clinical trial populations.

News All Time

Sevabertinib Approved for First-Line Mutated NSCLC

The oral HER2 TKI was previously given accelerated approval in the second line for the indication.

A New PARADIGM? Azacitidine-Venetoclax Tops Chemo in AML

The less-intensive drug combination outperforms standard induction chemotherapy in fit patients with acute myeloid leukemia.

FDA Approves Camizestrant for ESR1-Mutated Breast Cancer

The accelerated approval enables an endocrine therapy switch when the ESR1 resistance mutation is detected, rather than waiting for evidence of disease progression.

Talc Powder Not Linked to Lung Cancer in Women

A study of US women finds no connection between talc powder use and lung cancer, though subgroup findings leave questions open.

Saturated Fat Tied to Worse Survival After Prostate Cancer

The association is driven by higher rates of death from cardiovascular disease and other cancers over 13 years.

Medication Self-Injection Embraced by Breast Cancer Patients

Women with breast cancer show interest in self-injecting their medication.

Can 80 Gy Radiation Boost Survival in Prostate Cancer?

A modest increase in radiation dose improves progression-free survival over 10 years among men with high-risk prostate cancer — but the overall survival benefits found in a French trial are uncertain.

Remote CBT for Insomnia Improves Symptoms During Chemo

A new randomized trial strengthens the case for managing cancer-related insomnia with cognitive-behavioral therapy.

Low Awareness of How to Spot Rare Breast Cancer Identified

Researchers survey US adults to assess their knowledge of inflammatory breast cancer.

Long-Acting Interferon Therapy Approved for ET

Ropeginterferon alfa-2b is designed to provide durable disease control.

Thymus Radiation Exposure Tied to Worse Lung Cancer Outcomes

The thymus is not routinely considered during thoracic radiotherapy planning, but new findings suggest that may need to change.

FDA Approves Rusfertide for Polycythemia Vera

Adding rusfertide to standard-of-care treatment cut phlebotomy rates by more than half in the phase 3 VERIFY trial.

Black Canadians Face Multiple Barriers to Blood Donation

Barriers to blood donations from Black people in Canada are rooted in racism and restrictive policies.

Laser Therapy Shows Promise for Brain Tumors

Researchers followed 787 patients with brain tumors treated with laser therapy for up to 5 years.

Can Accelerated Salvage RT Improve Prostate Cancer Control?

After biochemical recurrence, hypofractionated RT may be no more effective than standard RT for disease control — and may have more late side effects.

Ibrutinib Fails in High-Risk Early-Stage CLL

Ibrutinib improves event-free survival in certain genetic subgroups of early-stage chronic lymphocytic leukemia but fails to extend overall survival.

Recommended News For You

Anti-PD-L1 Plus Targeted Agent No Better Than Chemo for Resistant NSCLC

Characterizing metastatic disease during adaptive therapy by using dynamic biomarkers and mathematical modeling.

NP-Led Outreach Ups Cancer Screening in Rural Women Veterans

Heavy Cannabis Use Tied to Increased Head and Neck Cancer Risk

Committee Recommends Canada Not Permit Euthanasia Solely for Mental Illness

Is There a Role for Stimulants in Beating Cancer Fatigue?

Certain surgical gestures during prostate removal linked to better sexual function recovery

Recommended Articles For You

Hematopoietic Resilience and Future Clinical Performance: Mechanisms, Clinical Implications, and Emerging Perspectives 

Critical Care Challenges in Oncologic Emergencies 

The latest research on Iron Binding Capacity: The Little-Known Factor That Could Impact Your Health v 

Protein S-Palmitoylation in Cancer: A Novel Target in Immunotherapy & Treatment 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Distinct results for patients with positive and negative pancreatic cancer who are treated with systemic therapy, chemotherapy, and radiation.

2.

Optimizing Sequencing of BCMA-Directed Therapies in Myeloma

3.

After all, Pulled Myeloma Drug May Help Treat the Illness.

4.

First-Line T-DXd Boosts PFS in HER2-Mutant NSCLC

5.

Breast awareness: What to look for in your self-exam

1.

Epigenetic Signatures for Multi-Cancer Screening

2.

Quality of Life Using Precision Functional Recovery After Organ-Preserving Interventions

3.

Exploring the Mystery of Angiokeratomas on Scrotum: Causes, Symptoms and Treatment

4.

Guidelines for Transfusion Threshold Assessment

5.

Exploring the Potential of Cytologic Atypia in Cancer Diagnosis

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Current Scenario of Cancer- The Incidence of Cancer in Men

2.

Nutrition During Cancer Treatment

3.

Future of Hematology

4.

Oropharyngeal Cancer in Relation to HPV Status

5.

Efficient Management of First line ALK-rearranged NSCLC - Part IV

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot